Item 5.02. Departure of Directors or Certain Officers; Election of Directors;


            Appointment of Certain Officers; Compensatory Arrangements of Certain
            Officers.

On January 5, 2021, Charles Albright, Ph.D., Chief Scientific Officer of Editas Medicine, Inc. (the "Company"), informed the Company that he will be resigning from his position effective January 15, 2021 to pursue another opportunity.




 Item 8.01. Other Events

On January 11, 2021, the Company registered for resale 303,599 shares of the Company's common stock, par value $0.0001 per share, pursuant to a prospectus supplement under its automatic shelf registration statement on Form S-3 (File No. 333-223596), filed with the Securities and Exchange Commission on March 12, 2018 (the "Registration Statement"). The opinion and consent of Wilmer Cutler Pickering Hale and Dorr LLP, as to the validity of these shares of common stock, filed as Exhibits 5.1 and 23.1 to this Current Report on Form 8-K, respectively, are incorporated by reference into the Registration Statement.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits



Exhibit
No.                                     Description
  5.1        Opinion of Wilmer Cutler Pickering Hale and Dorr LLP
  23.1       Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in
           Exhibit 5.1)
104        Cover Page Interactive Data File (embedded within the Inline XBRL
           document)

© Edgar Online, source Glimpses